Markets have been turning mostly up since the election, as investors have taken the measure of the macro environment and appear pleased. There …
Arguably the most controversial on the Street, penny stocks are a hot-button issue. Usually, there isn’t a lot of middle-ground with respect to …
Recro Pharma (NASDAQ:REPH) received devastating news on Thursday. The U.
Recro Pharma (NASDAQ:REPH) announced today that its lead compound, IV Meloxicam, received a CRL from the FDA, which is a nice way of saying …
Recro Pharma Inc (NASDAQ:REPH) investors have a smile on their faces Monday evening, after the drug maker announced that they have entered into an …
Brean Capital analyst Jonathan Aschoff came out with a favorable report on Recro Pharma Inc (NASDAQ:REPH) following several investor meetings with the company’s management. …
Brean Capital’s analyst Jonathan Aschoff came out today with a research note on Recro Pharma Inc (NASDAQ:REPH), maintaining a price target of $26 …
